The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

April 30, 2021

Study Completion Date

September 30, 2022

Conditions
OverdoseRisk Behavior
Interventions
BEHAVIORAL

Co-Dispensing

"Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use."

Trial Locations (1)

80204

Denver Health, Denver

All Listed Sponsors
collaborator

Denver Health and Hospital Authority

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Kaiser Permanente

OTHER

NCT03337100 - The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy | Biotech Hunter | Biotech Hunter